Palonosetron

Helsinn announces publication of data evaluating impact of AKYNZEO® (fosnetupitant/palonosetron) on treatment outcomes and healthcare costs

Retrieved on: 
Monday, June 12, 2023

The dataset provides insight to nearly 80% of the US healthcare system, with patient-level data from all provider types.

Key Points: 
  • The dataset provides insight to nearly 80% of the US healthcare system, with patient-level data from all provider types.
  • Referring to the details of the publication below, these real-world data showed that healthcare resource utilization, such as CINV-related visits were significantly lower after AKYNZEO® compared to fosaprepitant/palonosetron (APPA).
  • CINV-related healthcare costs were also statistically and/or numerically lower for patients receiving AKYZNEO® compared to APPA.
  • There remains a gap between expected and actual patient outcomes as clinicians translate trial data and clinical guidelines into practice.

Knight Therapeutics Reports Fourth Quarter and Year-End 2022 Results

Retrieved on: 
Thursday, March 23, 2023

Selling and marketing: For the quarter ended December 31, 2022, S&M increased by $2,111 or 17%.

Key Points: 
  • Selling and marketing: For the quarter ended December 31, 2022, S&M increased by $2,111 or 17%.
  • General and administrative: For the quarter ended on December 31, 2022, there was no significant variation in General and administrative expenses.
  • Research and development expenses: For the quarter ended on December 31, 2022, there was no significant variation in Research and development expenses.
  • In addition, during the fourth quarter of 2022, Knight also submitted a branded generic of for regulatory approval in Chile and Colombia.

Helsinn announces publication of new data evaluating impact of NEPA (netupitant/palonosetron) on hospital costs

Retrieved on: 
Friday, February 3, 2023

The article, “Antiemetic Use and Chemotherapy Induced Nausea and Vomiting related Hospitalization Costs After Highly or Moderately Emetogenic Chemotherapy”, evaluates the effect of NEPA on chemotherapy-induced nausea and vomiting (CINV)-related hospitalization costs.

Key Points: 
  • The article, “Antiemetic Use and Chemotherapy Induced Nausea and Vomiting related Hospitalization Costs After Highly or Moderately Emetogenic Chemotherapy”, evaluates the effect of NEPA on chemotherapy-induced nausea and vomiting (CINV)-related hospitalization costs.
  • NEPA was compared to aprepitant/fosaprepitant-containing regimens among patients who received highly or moderately emetogenic chemotherapy in the US.
  • The study findings suggest that the downstream economic impact of antiemetic choice may differ depending on the combination of treatments.
  • Hospitalizations with CINV as the primary reason for admission were identified and all incurred costs for these hospital stays were used in the cost accounting.

Helsinn and Immedica enter exclusive partnership for commercialisation of cancer supportive care products in core European markets

Retrieved on: 
Tuesday, January 24, 2023

Under the licence and distribution agreement Immedica will commercialise AKYNZEO® in Portugal, Spain, France, Switzerland, the Netherlands, Belgium, Luxembourg and Liechtenstein, ALOXI® in Switzerland, Belgium, Liechtenstein.

Key Points: 
  • Under the licence and distribution agreement Immedica will commercialise AKYNZEO® in Portugal, Spain, France, Switzerland, the Netherlands, Belgium, Luxembourg and Liechtenstein, ALOXI® in Switzerland, Belgium, Liechtenstein.
  • Anders Edvell, CEO of Immedica commented: “We are very pleased to have signed this agreement with Helsinn.
  • Side-effects of cancer treatments have a significant impact on the quality of life of these severely ill patients.
  • We look forward to working closely with Immedica in the months and years ahead to ensure more and more patients can access these important supportive care products.”

Knight Announces Relaunch of AKYNZEO® in Canada

Retrieved on: 
Thursday, December 1, 2022

MONTREAL, Dec. 01, 2022 (GLOBE NEWSWIRE) -- Knight Therapeutics Inc., (TSX: GUD) ("Knight") a pan-American (ex-USA) specialty pharmaceutical company, announced today that it has assumed full commercial activities and is relaunching oral AKYNZEO (netupitant/palonosetron capsules) in Canada.

Key Points: 
  • MONTREAL, Dec. 01, 2022 (GLOBE NEWSWIRE) -- Knight Therapeutics Inc., (TSX: GUD) ("Knight") a pan-American (ex-USA) specialty pharmaceutical company, announced today that it has assumed full commercial activities and is relaunching oral AKYNZEO (netupitant/palonosetron capsules) in Canada.
  • Knight and Helsinn Healthcare SA ("Helsinn") entered into an exclusive license, distribution and supply agreement for oral/IV AKYNZEO in Canada, Brazil, Argentina, Uruguay and Paraguay, and ALOXI oral/IV (palonosetron) in Canada (the "Products") in May 2022.
  • According to IQVIA, sales of AKYNZEO in Canada and Brazil were approximately $7 million in 2021.
  • Knight Therapeutics Inc., headquartered in Montreal, Canada, is a specialty pharmaceutical company focused on acquiring or in-licensing and commercializing pharmaceutical products for Canada and Latin America.

Helsinn announces presentation on CINV trial at European Society for Medical Oncology (ESMO) Asia

Retrieved on: 
Tuesday, November 29, 2022

Lugano, Switzerland, November 29, 2022 - Helsinn Group (Helsinn), a fully integrated global biopharma company with a track record of over forty years of commercial execution and a strong focus in oncology and rare diseases announces, announces its poster presentation at the upcoming European Society for Medical Oncology (ESMO) Asia Congress, being held in Singapore from 2-4 December.

Key Points: 
  • Lugano, Switzerland, November 29, 2022 - Helsinn Group (Helsinn), a fully integrated global biopharma company with a track record of over forty years of commercial execution and a strong focus in oncology and rare diseases announces, announces its poster presentation at the upcoming European Society for Medical Oncology (ESMO) Asia Congress, being held in Singapore from 2-4 December.
  • Full details of the poster presentation are below:
    Dr Silvia Sebastiani, Helsinn Group Head of Medical Affairs, commented: We are pleased to present the design of this important ongoing study at the ESMO Asia congress.
  • Despite the array of effective antiemetics, CINV still represents a huge unmet need in clinical practice.
  • Available at: http://www.mascc.org/ /
    2 NCCN: National Comprehensive Cancer Network; NCCN Clinical Practice Guidelines in Oncology; Version 2.2022.

Knight Therapeutics announces relaunch of AKYNZEO® in Brazil

Retrieved on: 
Monday, July 4, 2022

MONTREAL, July 04, 2022 (GLOBE NEWSWIRE) -- Knight Therapeutics Inc., (TSX: GUD) ("Knight") a pan-American (ex-USA) specialty pharmaceutical company, announced today that its Brazilian affiliate, United Medical Ltd., is assuming full commercial activities and is relaunching AKYNZEO (netupitant / palonosetron) in Brazil.

Key Points: 
  • MONTREAL, July 04, 2022 (GLOBE NEWSWIRE) -- Knight Therapeutics Inc., (TSX: GUD) ("Knight") a pan-American (ex-USA) specialty pharmaceutical company, announced today that its Brazilian affiliate, United Medical Ltd., is assuming full commercial activities and is relaunching AKYNZEO (netupitant / palonosetron) in Brazil.
  • According to IQVIA, sales of AKYNZEO in Canada and Brazil were approximately $7 million in 2021.
  • For more information about Knight Therapeutics Inc., please visit the company's web site at www.gud-knight.com or www.sedar.com .
  • Factors and risks, which could cause actual results to differ materially from current expectations are discussed in Knight Therapeutics Inc.'s Annual Report and in Knight Therapeutics Inc.'s Annual Information Form for the year ended December 31, 2021 as filed on www.sedar.com .

Knight Therapeutics Reports First Quarter 2022 Results

Retrieved on: 
Thursday, May 12, 2022

Amortization of intangible assets: For the quarter ended March 31, 2022, amortization of intangible assets increased by $5,986 due to the acquisition of Exelon.

Key Points: 
  • Amortization of intangible assets: For the quarter ended March 31, 2022, amortization of intangible assets increased by $5,986 due to the acquisition of Exelon.
  • Adjusted EBITDA: For the quarter ended March 31, 2022, adjusted EBITDA increased by $7,732 or 139%.
  • Net loss or income: For the quarter ended March 31, 2022, net loss was $18,811 compared to net income of $3,558 for the same period in prior year.
  • Knight obtained regulatory approval and launched Lenvima, Halaven and Rembre in Colombia during the first quarter of 2022.

Knight Therapeutics and Helsinn Healthcare SA Enter into Exclusive License, Distribution, and Supply Agreement for Akynzeo® and Aloxi®

Retrieved on: 
Thursday, May 12, 2022

Under the terms of the agreement, Knight shall have the exclusive right to distribute, promote, market and sell the Products in the licensed territories.

Key Points: 
  • Under the terms of the agreement, Knight shall have the exclusive right to distribute, promote, market and sell the Products in the licensed territories.
  • We are very excited to enter into this agreement with Helsinn for AKYNZEO in Canada, Brazil and other selected Latin American countries, and ALOXI in Canada, said Samira Sakhia, President and CEO of Knight.
  • AKYNZEO and ALOXI are leading, guideline-recommended1,2,3 antiemetics that help to prevent one of the most common side effects of chemotherapy.
  • AKYNZEO and ALOXI form a key part of Helsinns commercial engine of supportive cancer care products, said Giorgio Calderari, Helsinn CEO.

Sunovion Presents New KYNMOBI® (apomorphine sublingual film) Study Data at the International Parkinson and Movement Disorder Society (MDS) Congress 2021

Retrieved on: 
Friday, September 10, 2021

Sunovion Pharmaceuticals Inc. (Sunovion) today announced the presentation of multiple posters highlighting KYNMOBI (apomorphine sublingual film) for the on-demand treatment of OFF episodes associated with Parkinsons disease (PD) at the International Parkinson and Movement Disorder Society (MDS) Virtual Congress, being held September 17-22, 2021.

Key Points: 
  • Sunovion Pharmaceuticals Inc. (Sunovion) today announced the presentation of multiple posters highlighting KYNMOBI (apomorphine sublingual film) for the on-demand treatment of OFF episodes associated with Parkinsons disease (PD) at the International Parkinson and Movement Disorder Society (MDS) Virtual Congress, being held September 17-22, 2021.
  • The presentations include post-hoc findings from the pivotal study (CTH-300) and findings from an ongoing long-term safety study (CTH-301) of KYNMOBI.
  • These episodes rarely impacted patients ability to continue treatment with KYNMOBI.
  • Do not use KYNMOBI if you are allergic to apomorphine hydrochloride or to any of the ingredients in KYNMOBI.